Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT836 in Advanced Solid Tumors
NCT07216105Phase 1Recruiting
- Sponsor
- Fate Therapeutics
- Start
- Nov 2025
- Primary completion
- Jan 2028
- Modality
- CAR-T Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT836 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer and 3 more (8 arms), sponsored by Fate Therapeutics. Primary endpoints: Number of participants with dose limiting toxicities and Severity of dose limiting toxicities. Started Nov 2025; status: recruiting.
02
Drugs
FT836
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)breast cancerovarian cancerendometrial carcinoma
Beyond the preview
Go deeper on NCT07216105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216105.